Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 오구택 | * |
dc.contributor.author | 신동해 | * |
dc.contributor.author | 심현보 | * |
dc.contributor.author | 손성근 | * |
dc.contributor.author | 이미니 | * |
dc.date.accessioned | 2016-08-28T12:08:12Z | - |
dc.date.available | 2016-08-28T12:08:12Z | - |
dc.date.issued | 2011 | * |
dc.identifier.issn | 1226-3613 | * |
dc.identifier.other | OAK-7937 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/221925 | - |
dc.description.abstract | A variety of benzylidenethiazole analogs have been demonstrated to inhibit 5-lipoxygenase (5-LOX). Here we report the anti-atherogenic potential of 5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione (HMB-TZD), a benzylidenethiazole analog, and its potential mechanism of action in LDL receptor-deficient (Ldlr -/-) mice. HMB-TZD Treatment reduced leukotriene B 4 (LTB 4) production significantly in RAW264.7 macrophages and SVEC4-10 endothelial cells. Macrophages or endothelial cells pre-incubated with HMB-TZD for 2 h and then stimulated with lipopolysaccharide or tumor necrosis factor-alpha (TNF-α) displayed reduced cytokine production. Also, HMB-TZD reduced cell migration and adhesion in accordance with decreased proinflammatory molecule production in vitro and ex vivo. HMB-TZD treatment of 8-week-old male Ldlr -/- mice resulted in significantly reduced atherosclerotic lesions without a change to plasma lipid profiles. Moreover, aortic expression of pro-atherogenic molecules involved in the recruitment of monocytes to the aortic wall, including TNF-α, MCP-1, and VCAM-1, was downregulated. HMB-TZD also reduced macrophage infiltration into atherosclerotic lesions. In conclusion, HMB-TZD ameliorates atherosclerotic lesion formation possibly by reducing the expression of proinflammatory molecules and monocyte/macrophage recruitment to the lesion. These results suggest that HMB-TZD, and benzylidenethiazole analogs in general, may have therapeutic potential as treatments for atherosclerosis. | * |
dc.language | English | * |
dc.title | 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 43 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 471 | * |
dc.relation.lastpage | 478 | * |
dc.relation.journaltitle | Experimental and Molecular Medicine | * |
dc.identifier.doi | 10.3858/emm.2011.43.8.053 | * |
dc.identifier.wosid | WOS:000294400000005 | * |
dc.identifier.scopusid | 2-s2.0-80052164898 | * |
dc.author.google | Choi J.-H. | * |
dc.author.google | Park J.-G. | * |
dc.author.google | Jeon H.J. | * |
dc.author.google | Kim M.-S. | * |
dc.author.google | Lee M.-R. | * |
dc.author.google | Lee M.-N. | * |
dc.author.google | Sonn S. | * |
dc.author.google | Kim J.-H. | * |
dc.author.google | Lee M.H. | * |
dc.author.google | Choi M.-S. | * |
dc.author.google | Park Y.B. | * |
dc.author.google | Kwon O.-S. | * |
dc.author.google | Jeong T.-S. | * |
dc.author.google | Lee W.S. | * |
dc.author.google | Shim H.B. | * |
dc.author.google | Shin D.H. | * |
dc.author.google | Oh G.T. | * |
dc.contributor.scopusid | 오구택(7007056663) | * |
dc.contributor.scopusid | 신동해(57217374185) | * |
dc.contributor.scopusid | 심현보(26635827900) | * |
dc.contributor.scopusid | 손성근(8628610900) | * |
dc.contributor.scopusid | 이미니(35285954900;56136972000) | * |
dc.date.modifydate | 20240123094756 | * |